Welcome to our dedicated page for Exicure SEC filings (Ticker: XCUR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Exicure, Inc. filings document a clinical-stage biotechnology issuer centered on burixafor (GPC-100) and hematologic disease development, along with the corporate governance and financing matters that support that operating structure. Its 8-K reports include financial results, liquidity disclosures, research and development expense trends, and clinical or regulatory events tied to the burixafor Phase 2 program and related license and collaboration arrangements.
Other filings record director and executive management changes, audit committee appointments, material agreements, shareholder voting matters, and capital-structure disclosures. Exicure's public records also describe intercompany financing activity involving KC Creation Co., Ltd. convertible bonds and the company's acquisition-related shift from its historical nucleic acid therapy platform to a hematologic-disease pipeline.
Exicure, Inc. reported that Nasdaq notified the company on May 28, 2026 that it was out of compliance with Nasdaq Listing Rule 5250(c)(1) because its Form 10-Q for the quarter ended March 31, 2026 was filed late.
The delay was attributed to extra time needed after changes in Exicure’s financial reporting personnel and related procedures. Exicure filed the delayed Form 10-Q on May 29, 2026 and believes this filing brings it back into compliance with the Nasdaq listing rule.
The company describes itself as a biotechnology business that has restructured, suspended prior clinical and development activities, and is now exploring strategic alternatives. Its lead program, obtained through a January 2025 acquisition, is being evaluated for improving stem cell mobilization in multiple myeloma, sickle cell disease, and to support cell and gene therapy.
Exicure, Inc. reported a net loss of $1.8 million for the three months ended March 31, 2026, compared with net income of $3.0 million a year earlier. The swing was driven by the absence of a prior-year $6.0 million lease-termination gain and lower other income, partly offset by sharply reduced operating expenses.
The company generated no revenue, with research and development expense falling to $0.3 million and general and administrative expense to $1.3 million. Cash and cash equivalents were $2.6 million and stockholders’ equity $2.1 million as of March 31, 2026, while total liabilities reached $10.7 million, including $7.0 million of contingent consideration tied to the GPCR USA acquisition.
Management states there is substantial doubt about Exicure’s ability to continue as a going concern, citing ongoing losses, limited cash, and the need for additional financing to support operations and strategic alternatives. The company is exploring transactions around its GPCR USA oncology program, which completed a Phase 2 trial in January 2026, and expects to pay a $1.0 million milestone to GPCR in common stock.
Exicure discloses material weaknesses in internal control over financial reporting, multiple ongoing legal matters, and recent Nasdaq notices related to listing-rule compliance, including a deficiency triggered by the delayed filing of this report. Management indicates it is working to remediate controls and regain and maintain compliance, but acknowledges continued listing and financing uncertainties.
Exicure, Inc. submitted a Form 12b-25 notifying the SEC that it could not timely file its Quarterly Report on Form 10-Q for the period ended March 31, 2026 and expects to file within the five‑day grace period under Exchange Act Rule 12b-25.
The company states preliminary, unaudited results: total revenue $0 for the quarter, an expected net loss of approximately $1,827,911 for the three months ended March 31, 2026 versus approximately $3,010,000 for the three months ended March 31, 2025. It expects cash and cash equivalents of approximately $2,504,054 as of March 31, 2026, versus approximately $3.7 million as of December 31, 2025. Management notes the figures are preliminary and subject to completion of its financial review.
Exicure, Inc. reported governance and management changes, including a new director and a new Chief Operating Officer. These updates focus on strengthening board oversight and operational leadership.
The Board appointed Yoontae Han as director and Audit Committee member, with an annual retainer of $20,000. It also named Dongho Lee as Chair of the Audit Committee. Separately, effective April 9, 2026, Exicure appointed Young Seung Ko, age 50, as Chief Operating Officer and amended its executive services agreement with Innocircle Advisors Inc. to add an extra monthly fee of $10,000 for COO services.
Exicure, Inc. has obtained preliminary court approval for a global settlement of stockholder derivative matters tied to previously disclosed litigation over past handling of research data and disclosures. The settlement covers actions in federal courts in Illinois and Delaware plus a stockholder demand to the board.
Under the proposed terms, Exicure will adopt and maintain a package of corporate governance reforms for at least four years, including a new board-level Research and Data Integrity Oversight Committee and a management-level Disclosure Committee. Defendants’ insurers, rather than the company, have agreed to pay $675,000 in plaintiffs’ attorneys’ fees and expenses, subject to final court approval. A settlement hearing is scheduled for June 2, 2026, and current stockholders as of March 18, 2026 may object by written submission ahead of that date.
Exicure, Inc. reported a change on its Board of Directors. On March 25, 2026, director Sangjin Yeo submitted his resignation from the Board and the Audit Committee, effective March 27, 2026. The company stated that his resignation did not result from any disagreement regarding its operations, policies, or practices. The report was signed on behalf of Exicure by Chief Executive Officer Jung Soo Kim.
Exicure, Inc. reports that it has halted its historical biotech R&D, sold essentially all prior intellectual property, and is now focused on exploring strategic alternatives, including acquisitions and partnerships, potentially outside biotechnology and with an emphasis on Asia.
At December 31, 2025, cash and cash equivalents were about $3.7 million, with a 2025 net loss of $4.9 million and an accumulated deficit of $223.0 million, leading to “substantial doubt” about its ability to continue as a going concern without near‑term financing.
The company acquired GPCR Therapeutics USA Inc. in January 2025; GPCR USA completed a Phase 2 trial in January 2026, and Exicure plans a $1.0 million milestone payment in stock in 2026. HiTron owns about 25% of common stock, increasing governance influence concerns. Risks include Nasdaq delisting, significant legal proceedings and settlements, difficulties redeeming $2.090 million of convertible notes, unpaid rent disputes of about $0.7 million, and limited internal controls and cybersecurity resources.
Exicure, Inc. reported a smaller net loss for 2025 but highlighted serious liquidity challenges. Net loss narrowed to $4.9 million from $9.7 million in 2024, helped by a $6.0 million gain from early termination of its Chicago office lease.
Cash and cash equivalents fell sharply to $3.7 million as of December 31, 2025, from $12.5 million a year earlier. Management states this cash is not sufficient to fund operations, and that substantial additional financing is needed in the short term to pay expenses and continue exploring strategic alternatives.
Following the acquisition of GPCR Therapeutics USA Inc., research and development expenses rose to $3.3 million from zero, while general and administrative expense increased to $6.8 million from $5.4 million, mainly due to acquisition and integration costs. Revenue was $0 in 2025 versus $0.5 million in 2024.
Exicure, Inc. Chief Accounting Officer Josh Miller reported a small tax-related share disposition. On February 16, 2026, 8 shares of common stock at $4.08 per share were withheld by Exicure to cover his tax obligation upon vesting of restricted stock units. After this withholding, Miller directly holds 301 shares of Exicure common stock. This was a tax-withholding disposition under code F, not an open-market sale.
Exicure, Inc. reported a leadership change, appointing Jung Soo Kim as Chief Executive Officer and President and Gyuyeob Lee as Interim Chief Financial Officer and Secretary, effective February 11, 2026. These appointments follow the resignations of former CEO and President Andy Yoo and former CFO and Secretary Seung Ik Baik, effective February 9, 2026.
The company highlights Mr. Kim’s more than 20 years of experience in corporate strategy, capital markets and restructuring, and Mr. Lee’s background in governance restructuring, financial planning and regulatory compliance, including their current roles at AGEDB Technology. Exicure’s board also approved that CEO and Interim CFO services will be provided under executive services agreements with Innocircle Advisors Inc.